Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients

2001 ◽  
Vol 38 (2, Suppl 4) ◽  
pp. 44-51 ◽  
Author(s):  
S. G. Courter ◽  
C. L. Bedrosian
Keyword(s):  
Factor Viii ◽  
Clinical Evaluation ◽  
Recombinant Factor Viii ◽  
Previously Treated Patients ◽  
Previously Treated

A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A

1997 ◽  
Vol 78 (05) ◽  
pp. 1352-1356 ◽  
Author(s):  
Emel Aygören-Pürsün ◽  
Inge Scharrer ◽  
Keyword(s):  
Factor Viii ◽  
Hemophilia A ◽  
Parvovirus B19 ◽  
Subjective Evaluation ◽  
Recombinant Factor Viii ◽  
Fviii Inhibitor ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Bleeding Episodes ◽  
Recombinant Fviii

SummaryIn this open multicenter study the safety and efficacy of recombinant factor VIII (rFVIII) was assessed in 39 previously treated patients with hemophilia A (factor VIII basal activity ≤15%).Recombinant FVIII was administered for prophylaxis and treatment of bleeding episodes and for surgical procedures. A total of 3679 infusions of rFVIII were given. Efficacy of rFVIII as assessed by subjective evaluation of response to infusion and mean annual consumption of rFVIII was comparable to that of plasma derived FVIII concentrates. The incremental recovery of FVIII (2.4 ± 0,83%/IU/kg, 2.12 ± 0.61%/IU/kg, resp.) was within the expected range. No clinical significant FVIII inhibitor was detected in this trial. Five of 16 susceptible patients showed a seroconversion for parvovirus B19. However, the results are ambiguous in two cases and might be explained otherwise in one further case. Thus, in two patients a reliable seroconversion for parvovirus B19 was observed.

scholarly journals Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII

2004 ◽  
Vol 126 (3) ◽  
pp. 398-404 ◽  
Author(s):  
Alessandro Gringeri ◽  
Annarita Tagliaferri ◽  
Giuseppe Tagariello ◽  
Massimo Morfini ◽  
Elena Santagostino ◽  
...  
Keyword(s):  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Inhibitor Development ◽  
Previously Treated Patients ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document